Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer

Clinical Cancer Research

Volumn 13, Issue 17, 2007, Pages 5103-5108

  Hessels, Daphne ^a   Smit, Frank P ^a   Verhaegh, Gerald W ^a   Witjes, J Alfred ^a   Cornel, Erik B ^b   Schalken, Jack A ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Twente Hospital Group   (Netherlands)

^c Gen Probe Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN REGULATED TRANSMEMBRANE SERINE PROTEASE 2; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; UNCLASSIFIED DRUG; MESSENGER RNA; ONCOPROTEIN; PROSTATE CANCER ANTIGEN 3, HUMAN; TMPRSS2 EGR FUSION PROTEIN, HUMAN; TMPRSS2-EGR FUSION PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; URINE SEDIMENT; GENETICS; MORTALITY; PROGNOSIS; PROSTATE TUMOR; URINE;

ANTIGENS, NEOPLASM; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 34548863661     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0700     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Evidence of recurrent gene fusions in common epithelial tumors. Trends Mol Med 2006;12:529-36.
3. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
4. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-52.
5. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2: ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396-400.
6. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9.
7. Tinzl M, Marberger M, Horvath S, Chypre C. DD3 PCA3 RNA analysis in urine - a new perspective for detecting prostate cancer. Eur Urol 2004;46:182-6.
8. Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64:311-5.
9. Laxman B, Tomlins SA, Mehra R, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006;8:885-8.
10. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15.
11. van Gils MP, Hessels D, van Hooij O, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007;13:939-43.
12. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci U S A 1984;81:1991-5.
13. Yoshimoto M, Joshua AM, Chilton-Macneill S, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006;8:465-9.
14. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-51.
15. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-41.
16. Cerveira N, Ribeiro FR, Peixoto A, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006;8:826-32.
17. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695-8.
18. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2006;26:2667-73.
19. Rajput AB, Miller MA, De LA, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007. Epub ahead of print.
20. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associatedwith lethal prostate cancer in a watchful waiting cohort. Oncogene 2007. Epub ahead of print.
21. Hessels D, Verhaegh GW, Schalken JA, Witjes JA. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn 2004;4:513-26.